Abstract:Backgroud Bevacizumab combined with modified FOLFOX6 (mFOLFOX6) is a standard regimen for colorectal cancer with good tolerability. Our previously published study by Sun et al showed a moderate efficacy and excellent safety of mFOLFOX6 for metastatic breast cancer (MBC). This study was to determine the efficacy and safety of adding bevacizumab to mFOLFOX6 in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-negative MBC. Patients and Methods In this open label, single-arm phase II study, bevacizumab, 5 mg/kg every two weeks or 7.5 mg/kg every three weeks, in combination with mFOLFOX6, which were oxaliplatin 85mg/m2, leucovorin 400mg/m2 and 5-Fu 400mg/m2 intravenously on day 1 following 5-Fu 2400 mg/m2 continuous intravenously 46 hours every 2 weeks, was administered to patients who failed at least 2 prior chemotherapy regimens in metastatic setting. The prior exposure to taxane, anthracycline, vinorelbine, capecitabine and gemcitabine was 97.9%, 93.8%, 64.6%, 64.6% and 81.3%, respectively. The primary objective was progression free survival (PFS), and secondary objectives included objective response rate (ORR), overall survival (OS) and safety. Results 48 patients were enrolled with a median of 49.5 years old (range, 34 to 73 years old) and a median of 3 prior chemotherapy regimens (range, 2 to 6). A median of 4.0 cycles (range, 0.5 to 8.0 cycles) were delivered with 45 patients undergoing treatment discontinuation, including 7 (14.6%) due to completion of 6 cycles, 1 (2.1%) due to completion of 8 cycles, 18 (37.5%) due to disease progression, 5 (10.4%) due to adverse events, 4 (8.3%) due to withdrawal of informed consent, 2 (4.2%) due to physician’s decision, 2 (4.2%) due to economic reasons and 6 (12.5%) with unknown causes. The median PFS was 6.0 months (95% confidence interval [CI], 3.6 to 8.5 months), ORR was 48.8% and median OS was 10.2 months (95% CI, 8.5 to 11.9 months). Most adverse events were grade 1 or 2 and grade 3 or 4 toxicities occurring in more than one patient were neutropenia (75.0%), leukopenia (50.0%), thrombocytopenia (20.8%) and anemia (6.3%). Conclusion Adding bevacizumab to mFOLFOX6 has significant anti-tumor activity and excellent safety in heavily pretreated HER2-negative MBC patients, which warrants conduct of further confirmative trials. Citation Format: Ting Li, Biyun Wang, Xichun Hu, Zhonghua Wang, Jian Zhang, Si Sun, Jun Cao, Fangfang Lv, Leiping Wang, Sheng Zhang, Chen Ni, Zhenhua Wu, Jie Xie. A phase II study of bevacizumab in combination with modified FOLFOX6 in heavily pretreated patients with HER2-negative metastatic breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-17-02.

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin Plus Paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma.

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin Plus Paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma (NCT02023710).

Atezolizumab Plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: a Multicenter, Open-label, Single-arm Phase 2 Study

Paclitaxel and carboplatin combined with antiangiogenesis therapy for patients with metastatic mucosal malignant melanoma

Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.

Salvage Therapy for Metastatic Acral or Mucosal Melanoma: Efficacy and Safety Analysis of Nab-Paclitaxel/carboplatin Combined with Bevacizumab in C-Kit/braf Wild-Type Pts.

Camrelizumab Combined with Anlotinib and Nab-Paclitaxel in Patients with Untreated Advanced Mucosal Melanoma: A Single-Arm, Multicenter, Exploratory Study.

Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC: Results from the Phase IV MO19390 (sail) Study

Multicenter, Randomized, Controlled, Open-Label Study of Bevacizumab Combined with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients with Metastatic Nasopharyngeal Carcinoma.

Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study.

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

A Multicenter, Single-Arm, Open-Label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination with Pembrolizumab and Nab-Paclitaxel in the First-Line Treatment of Patients with Unresectable/metastatic Mucosal Melanoma.

Axitinib in Combination with Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients with Metastatic Mucosal Melanoma: an Open-Label Phase IB Trial

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

A Phase II Study of Vorolanib (CM082) in Combination with Toripalimab (JS001) in Patients with Advanced Mucosal Melanoma.

Abstract P2-17-02: A phase II study of bevacizumab in combination with modified FOLFOX6 in heavily pretreated patients with HER2-negative metastatic breast cancer

A Phase I Trial of Ipilimumab Plus Bevacizumab in Patients with Unresectable Stage Iii or Stage Iv Melanoma

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study